Ironwood Pharmaceuticals, Inc. Announces 2024 Annual Meeting of Stockholders

TL;DR

<b>Ironwood Pharmaceuticals will hold its 2024 virtual Annual Meeting of Stockholders on June 18, 2024, to elect directors, vote on executive compensation, and ratify auditors.</b>

AI Summary

IRONWOOD PHARMACEUTICALS INC (IRWD) filed a Proxy Statement (DEF 14A) with the SEC on April 25, 2024. The 2024 Annual Meeting of Stockholders for Ironwood Pharmaceuticals, Inc. will be held virtually on June 18, 2024, at 9:00 a.m. Eastern Time. Stockholders will vote on three company-sponsored proposals: election of nine director nominees, an advisory vote on executive compensation, and ratification of Ernst & Young LLP as auditors. The board of directors recommends voting 'for' all nine director nominees. The board of directors recommends voting 'for' the advisory vote on named executive officer compensation. The board of directors recommends voting 'for' the ratification of Ernst & Young LLP as auditors for 2024.

Why It Matters

For investors and stakeholders tracking IRONWOOD PHARMACEUTICALS INC, this filing contains several important signals. This filing is a proxy statement (DEF 14A) detailing the proposals to be voted on at the annual meeting, including director elections and executive compensation. The meeting's virtual format allows broader participation, and the proposals reflect standard corporate governance practices, including auditor ratification.

Risk Assessment

Risk Level: low — IRONWOOD PHARMACEUTICALS INC shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain significant new financial or strategic information that would alter the company's risk profile.

Analyst Insight

Stockholders should review the director nominees and executive compensation details to make informed voting decisions at the upcoming annual meeting.

Key Numbers

• June 18, 2024 — Annual Meeting Date (2024 Annual Meeting of Stockholders)
• 9:00 a.m. Eastern Time — Annual Meeting Time (2024 Annual Meeting of Stockholders)
• 9 — Director Nominees (Proposal 1: To elect nine director nominees)
• 2024 — Auditor Year (Ratify Ernst & Young LLP as our auditors for 2024)
• April 19, 2024 — Record Date (Stockholders of record at the close of business on April 19, 2024)

Key Players & Entities

• IRONWOOD PHARMACEUTICALS, INC. (company) — Registrant
• Mark Currie, Ph.D. (person) — Director nominee
• Alexander Denner, Ph.D. (person) — Director nominee
• Andrew Dreyfus (person) — Director nominee
• Jon Duane (person) — Director nominee
• Marla Kessler (person) — Director nominee
• Thomas McCourt (person) — Director nominee
• Julie McHugh (person) — Director nominee

FAQ

Risk Factors

• Compliance with SEC Regulations [low — regulatory]: The company must comply with all SEC rules and regulations regarding proxy solicitations and annual meetings.
• Virtual Meeting Format [low — operational]: Conducting the annual meeting virtually requires robust technology and clear communication to ensure stockholder participation.
• Auditor Ratification [low — financial]: Stockholder approval of the auditor is a standard governance practice that impacts financial reporting reliability.

Key Dates

• 2024-06-18: Annual Meeting of Stockholders — To elect directors, vote on executive compensation, and ratify auditors.
• 2024-04-19: Record Date — Determines which stockholders are entitled to vote at the annual meeting.

Key Financial Figures

• $430.5 million — 1. Maximize LINZESS We recognized $430.5 million in collaborative arrangements revenue r
• $31.7 million — ended December 31, 2023, an increase of $31.7 million compared to the year ended December 31,
• $400 million — o acquisition was partially funded with $400 million of borrowings under a new revolving cre
• $1.0 b — recognized a net loss of approximately $1.0 billion, which included a non-recurring c
• $1.1 billion — a non-recurring charge of approximately $1.1 billion for acquired in-process research and de
• $183.4 million — e VectivBio acquisition. We generated $183.4 million in cash from operations during the year
• $92.2 million — December 31, 2023, ending the year with $92.2 million in cash and cash equivalents. As we c

Filing Documents

• tm2328525d4_def14a.htm (DEF 14A) — 1847KB
• bc_ebitda-4c.jpg (GRAPHIC) — 66KB
• bc_line-4c.jpg (GRAPHIC) — 2KB
• bc_netincome-4c.jpg (GRAPHIC) — 62KB
• bc_tsr-4c.jpg (GRAPHIC) — 57KB
• cov_ofc-4c.jpg (GRAPHIC) — 346KB
• cv_ibc-4c.jpg (GRAPHIC) — 64KB
• cv_ifc-4c.jpg (GRAPHIC) — 56KB
• cv_obc-4c.jpg (GRAPHIC) — 50KB
• hr_greenltsm-4c.jpg (GRAPHIC) — 5KB
• htr_bluegreen-4c.jpg (GRAPHIC) — 11KB
• htr_greenorange-4c.jpg (GRAPHIC) — 11KB
• htr_greenorangebanner-4c.jpg (GRAPHIC) — 4KB
• ic_check-pn.gif (GRAPHIC) — 3KB
• ic_prop1-bw.gif (GRAPHIC) — 4KB
• ic_prop2-bw.gif (GRAPHIC) — 5KB
• ic_prop3-bw.gif (GRAPHIC) — 5KB
• lc_index-4c.jpg (GRAPHIC) — 41KB
• lg_ironwood-bw.jpg (GRAPHIC) — 39KB
• pc_ceocompensation-4c.jpg (GRAPHIC) — 24KB
• pc_neoscompensation-4c.jpg (GRAPHIC) — 24KB
• ph_ironwood-4c.jpg (GRAPHIC) — 72KB
• ph_thomasmccourtbg-4c.jpg (GRAPHIC) — 17KB
• px_24ironwoodproxy01pg01-bw.jpg (GRAPHIC) — 254KB
• px_24ironwoodproxy01pg02-bw.jpg (GRAPHIC) — 204KB
• sg_thomasmccourt-bw.jpg (GRAPHIC) — 6KB
• 0001104659-24-051992.txt (&nbsp;) — 6410KB
• irwd-20231231.xsd (EX-101.SCH) — 9KB
• irwd-20231231_def.xml (EX-101.DEF) — 8KB
• irwd-20231231_lab.xml (EX-101.LAB) — 30KB
• irwd-20231231_pre.xml (EX-101.PRE) — 11KB
• tm2328525d4_def14a_htm.xml (XML) — 337KB

Executive Compensation

Executive Compensation 33 Compensation Discussion and Analysis 33 Compensation Tables 54 CEO Pay Ratio 64 Pay Versus Performance 65 Proposal No. 2 Advisory Vote on Named Executive Officer Compensation 72 Our Stockholders 74 Certain Relationships and Related Person Transactions 77 Proposal No. 3 Ratification of our Selection of Auditors 78 User's Guide 80 Stockholder Communications, Proposals and Nominations for Directorships 84 SEC Filings 85 i Ironwood TABLE OF CONTENTS Letter From Our CEO Dear Ironwood stockholders, I am pleased to share our progress towards realizing our vision of becoming the leading GI healthcare company. At Ironwood, our mission is to advance the treatment of GI diseases and redefine the standard of care for GI patients. This guiding mission drives us to deliver game-changing GI treatments to patients in need and to do good in the communities in which we and our stakeholders live and work. To uphold these commitments, we remain anchored by our three clearly defined objectives: 1) maximize LINZESS, 2) advance our GI pipeline, and 3) deliver sustained profits and cash flows. Our blockbuster product, LINZESS, in its 11 th year on the market, had a successful 2023, with U.S. net sales increasing by 7% compared to the prior year, driven by continued robust prescription demand growth of 10% year-over-year. Notably, new-to-brand prescriptions saw a significant ramp-up, increasing by 15% compared to 2022, which we believe is a key indicator of future growth potential of LINZESS. LINZESS reached an all-time high of 46% in total prescriptions (TRx) share in the combined branded and generic IBS-C and CIC market, further solidifying its leadership position. In June 2023, LINZESS received U.S. FDA approval to become the first and only approved prescription therapy for patients ages 6 to 17 years old with functional constipation, providing an important opportunity to expand its clinical utility i

View Full Filing

View this DEF 14A filing on SEC EDGAR